We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

85 hedge funds and large institutions have $142M invested in Antares Pharma, Inc. in 2017 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

360% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 5

186% more call options, than puts

Call options by funds: $372K | Put options by funds: $130K

85% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 13

20% more funds holding

Funds holding: 71 → 85 (+14)

18% more capital invested

Capital invested by funds: $121M → $142M (+$21.2M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
85
Holders Change
+14
Holders Change %
+19.72%
% of All Funds
2.12%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
24
Reduced
13
Closed
5
Calls
$372K
Puts
$130K
Net Calls
+$242K
Net Calls Change
+$176K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.96M
2
Millennium Management
Millennium Management
New York
+$3.7M
3
RCMNY
Rubric Capital Management (New York)
New York
+$2.9M
4
Morgan Stanley
Morgan Stanley
New York
+$1.45M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.39M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$12.8M
2
AC
Armistice Capital
New York
-$5.53M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$2.15M
4
KCM
Kingdon Capital Management
New York
-$525K
5
JHIU
Janus Henderson Investors US
Colorado
-$434K
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$561K -$331K -137,564 -41%
Baird Financial Group
27
Baird Financial Group
Wisconsin
$560K -$5.29K -2,201 -1%
SCM
28
Segantii Capital Management
Hong Kong
$537K +$385K +160,200 +552%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$476K +$67.4K +28,029 +20%
ARTA
30
A.R.T. Advisors
New York
$472K +$400K +166,414 New
BCM
31
BlueCrest Capital Management
Jersey
$431K +$365K +151,730 New
Deutsche Bank
32
Deutsche Bank
Germany
$393K +$333K +138,459 New
Jacobs Levy Equity Management
33
Jacobs Levy Equity Management
New Jersey
$393K +$333K +138,512 New
CIBC Private Wealth Group
34
CIBC Private Wealth Group
Georgia
$355K – – –
V
35
Veritable
Delaware
$311K +$71K +29,500 +37%
PNC Financial Services Group
36
PNC Financial Services Group
Pennsylvania
$284K – – –
GP
37
GLG Partners
United Kingdom
$242K +$205K +85,363 New
Citadel Advisors
38
Citadel Advisors
Florida
$238K +$157K +65,262 +350%
M&T Bank
39
M&T Bank
New York
$227K +$192K +80,000 New
State Street
40
State Street
Massachusetts
$206K – – –
TDC
41
Thompson Davis & Co
Virginia
$194K +$73.5K +30,560 +81%
VKH
42
Virtu KCG Holdings
New York
$189K +$52.6K +21,881 +49%
SIC
43
SFE Investment Counsel
California
$170K – – –
Verition Fund Management
44
Verition Fund Management
Connecticut
$167K +$141K +58,754 New
OC
45
Oppenheimer & Co
New York
$162K -$45.7K -19,000 -25%
JG
46
Jefferies Group
New York
$156K -$277K -115,000 -68%
NPC
47
National Planning Corporation
California
$153K – – –
CS
48
Credit Suisse
Switzerland
$146K +$124K +51,532 New
LPL Financial
49
LPL Financial
California
$140K +$34.6K +14,391 +42%
Commonwealth Equity Services
50
Commonwealth Equity Services
Massachusetts
$126K -$3.11K -1,294 -3%
1
2
3 4

ATRS Hedge Fund Activity: Q1 2017 in Review

85 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2017, worth a combined $142M — up 18% from $121M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ATRS positions and 5 closed out — a net gain of 18 holders — while 24 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $6.96M. The largest seller was Broadfin Capital, cutting an estimated $12.8M.

  • 85 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2017, up from 71 in Q4 2016.
  • Funds reported $142M of Antares Pharma, Inc. stock for Q1 2017, up 18% quarter-over-quarter.
  • 23 funds opened new Antares Pharma, Inc. positions in Q1 2017 and 5 closed out, a net change of +18 holders.
  • The largest Antares Pharma, Inc. buyer in Q1 2017 was BlackRock, an estimated $6.96M added.
  • The largest Antares Pharma, Inc. seller in Q1 2017 was Broadfin Capital, an estimated $12.8M sold.

Based on aggregated 13F filings for Q1 2017.